Tumor microenvironment-responsive metal nanotherapeutics for breast cancer chemo-/immunotherapy

Jinggong Liu,Wenying Li,Yongpeng Lin,Yongjun Peng,Meixiao Zhan,Haoqiang Lai,Yanzhou Chang,Yongjin Li,Ka-hing Wong,Bolai Chen,Tianfeng Chen

DOI: https://doi.org/10.1038/s41427-023-00473-0

IF: 10.761

2023-04-28

NPG Asia Materials

Abstract:Many metal complexes not only had excellent cytotoxic antitumor effects but also could function as a positive immunomodulatory to improve antitumor effects by modifying the local tumor microenvironment. Herein, a dual-target nanotherapeutics (MP3/ACPP/AE105@NPs) with uPAR targeting and tumor microenvironment-responsive ability was developed by using AE105 as the targeting ligand and ACPP as the tumor microenvironment-responsive peptide to locate the metal complex to cells. Assisted by the surface modification, MP3/ACPP/AE105@NPs demonstrated excellent cellular uptake of the drugs in in vitro experiments, thereby enhancing the therapeutic utility of the loaded metal complex. The nanotherapeutics induced the excessive ROS generation by inhibiting the activity of TrxR and modulated those proteins which were related to metastasis through inhibiting ERK/AKT activation mediated by FAK in MDA-MB-231 cells. This nanotherapeutics could also significantly improve the therapeutic benefits in vivo accompanied by reduced toxic side effects. Importantly, MP3/ACPP/AE105@NPs treatment stimulated immunotherapeutic response, which was indicated by the activation of tumor-infiltrated cytotoxic T cells, and improved the maturation of dendritic cells (DCs), and the proliferation-inhibitory effect of tumor-associated M2 macrophages. Taken together, the results suggested that this dual-targeted nanotherapeutics offered new opportunities for boosting the synergistic treatment of breast cancer with chemotherapy and immunotherapy.

materials science, multidisciplinary

What problem does this paper attempt to address?

The problems that this paper attempts to solve mainly focus on the synergy between chemotherapy and immunotherapy for breast cancer. Specifically, the researchers have developed a dual - targeted nano - therapeutic agent (MP3/ACPP/AE105@NPs), aiming to enhance the anti - tumor effect by regulating the tumor microenvironment and reduce the toxic side effects on normal tissues. The following are the specific problems that this study attempts to solve:

1. **Improve the targeting and efficacy of chemotherapy drugs**: By using specific targeting peptides (such as ACPP and AE105), the metal complex can be more accurately targeted to tumor cells, thereby improving the effect of chemotherapy drugs.

2. **Reduce the toxic side effects of chemotherapy drugs**: Although traditional chemotherapy drugs such as cisplatin are effective, they also have great toxicity to normal organs. The researchers hope to improve this problem through nanotechnology and reduce the impact of drugs on non - tumor cells.

3. **Activate the immune response**: In addition to the direct anti - cancer effect, the study also explored whether the nano - therapeutic agent can enhance the effect of immunotherapy by activating tumor - infiltrating cytotoxic T cells, promoting the maturation of dendritic cells and inhibiting the proliferation of tumor - associated M2 macrophages.

4. **Inhibit tumor metastasis and invasion**: The study found that MP3/ACPP/AE105@NPs can inhibit the migration and invasion ability of MDA - MB - 231 cells by inhibiting the FAK - mediated ERK/AKT signaling pathway and down - regulating the expression of proteins related to metastasis.

5. **Interfere with the intracellular redox balance**: The study also explored whether MP3/AA@NPs can increase the intracellular ROS level by inhibiting TrxR activity, and then induce cancer cell apoptosis.

In summary, the main purpose of this study is to develop a new type of dual - targeted nano - therapeutic agent, in order to improve the effect of breast cancer chemotherapy, enhance the role of immunotherapy and reduce the toxic side effects of drugs.